Guillaume Charpentier
Overview
Explore the profile of Guillaume Charpentier including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
114
Citations
10178
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Delplanque J, Le Collen L, Loiselle H, Leloire A, Toussaint B, Vaillant E, et al.
Am J Hum Genet
. 2024 Nov;
111(12):2668-2674.
PMID: 39561769
Individuals with obesity caused by biallelic pathogenic LEPR (leptin receptor) variants can benefit from setmelanotide, the novel MC4R agonist. An ongoing phase 3 clinical trial (NCT05093634) includes individuals with obesity...
2.
Dardari D, Piaggesi A, Potier L, Sultan A, Diener H, Francois M, et al.
NEJM Evid
. 2024 Oct;
3(12):EVIDoa2400171.
PMID: 39365895
Background: Diabetic foot ulcers are chronic, difficult to heal, and potentially life-threatening. Few medical devices have been studied in diabetic ulcers penetrating to bone or tendon. Methods: We conducted an...
3.
Meulebrouck S, Merrheim J, Queniat G, Bourouh C, Derhourhi M, Boissel M, et al.
Nat Commun
. 2024 Aug;
15(1):6627.
PMID: 39103322
Functional genetics has identified drug targets for metabolic disorders. Opioid use impacts metabolic homeostasis, although mechanisms remain elusive. Here, we explore the OPRD1 gene (encoding delta opioid receptor, DOP) to...
4.
Lebbad H, Desir C, Vesin A, Adenis A, Charpentier G, Benhamou P
J Diabetes Sci Technol
. 2024 May;
:19322968241252366.
PMID: 38804537
Background: The prediction of the individual insulin needs may facilitate the initiation of insulin therapy. Our aim was to explore the relationships between body weight, sex, and daily amounts of...
5.
Folon L, Baron M, Scherrer V, Toussaint B, Vaillant E, Loiselle H, et al.
Diabetes Care
. 2024 Jan;
47(3):444-451.
PMID: 38170957
Objective: Rare variants in DYRK1B have been described in some patients with central obesity, type 2 diabetes, and early-onset coronary disease. Owing to the limited number of conducted studies, the...
6.
Dance A, Fernandes J, Toussaint B, Vaillant E, Boutry R, Baron M, et al.
Mol Metab
. 2023 Dec;
79:101867.
PMID: 38159881
Objective: Human functional genomics has proven powerful in discovering drug targets for common metabolic disorders. Through this approach, we investigated the involvement of the purinergic receptor P2RY1 in type 2...
7.
Meulebrouck S, Scherrer V, Boutry R, Toussaint B, Vaillant E, Dechaume A, et al.
Diabetologia
. 2023 Dec;
67(2):327-332.
PMID: 38051360
Aims/hypothesis: GLIS3 encodes a transcription factor involved in pancreatic beta cell development and function. Rare pathogenic, bi-allelic mutations in GLIS3 cause syndromic neonatal diabetes whereas frequent SNPs at this locus...
8.
Franc S, Bensaid S, Schaepelynck P, Orlando L, Lopes P, Charpentier G
Diabetes Metab
. 2023 Oct;
49(6):101486.
PMID: 37858921
Many studies have clearly established that chronic psychosocial stress may sustainably worsen glycemic control in patients with type 1 diabetes mellitus (T1DMM), thus promoting diabetes complications. Chronic psychosocial stress may...
9.
Blervaque J, Lablanche S, Romero-Ugalde H, Adenis A, Charpentier G, Benhamou P
Diabetes Care
. 2023 Sep;
46(10):e207-e208.
PMID: 37729499
No abstract available.
10.
Gao W, Liu L, Huh E, Gbahou F, Cecon E, Oshima M, et al.
Nat Metab
. 2023 Sep;
5(10):1673-1684.
PMID: 37709961
The glucagon-like peptide 1 receptor (GLP1R) is a major drug target with several agonists being prescribed in individuals with type 2 diabetes and obesity. The impact of genetic variability of...